摘要
目的:观察复方玄驹胶囊对慢性前列腺炎合并勃起功能障碍(ED)的治疗效果及安全性。方法:132例慢性前列腺炎伴发ED患者,治疗前行NIH慢性前列腺炎症状评分(NIH-CPSI)及国际勃起功能指数问卷5(IIEF-5)评分。根据治疗方式不同,将患者分为对照组(70例)及治疗组(62例)。对照组使用左氧氟沙星0.2 g,口服,2/d,连续服用4～6周,及特拉唑嗪2 mg,口服,1/晚,连续服用2个月。治疗组在上述治疗的基础上,同时使用复方玄驹胶囊2粒,口服,3/d,连续服用2个月。结果:所有患者均无严重不良反应出现,能坚持服药。治疗后2个月重新评分,对照组NIH-CPSI平均(16.5±5.9)分,较治疗前(25.1±5.5)分显著改善(P<0.05),IIEF-5平均(13.1±5.2)分,较治疗前(11.3±4.5)分有所增加,但差异无显著性(P>0.05);治疗组NIH-CPSI平均(13.4±5.7)分,IIEF-5平均(17.5±6.5)分,与治疗前比较,均改善显著(P<0.05)。对照组ED总有效率为20%,治疗组ED总有效率为74.2%,其差异有显著性(P<0.05)。结论:复方玄驹胶囊治疗慢性前列腺炎伴发ED,既可明显改善慢性前列腺炎症状,同时,对伴发的ED也有较好的疗效,无严重不良反应,值得推广使用。
Objective： To evaluate the efficacy and safety of Compound Xuanju Capsule（CXC） in the treatment of chronic prostatitis with erectile dysfunction（ED）.Methods： We obtained NIH-CPSI and IIEF-5 scores from 132 chronic prostatitis patients with ED and divided the patients into a control（n=70） and a treatment group（n=62）,the former treated with oral levofloxacin 0.2g bid for 4-6 weeks and oral Terazosin at 2 mg qd for 2 months,and the latter with oral CXC once 2 capsules tid for 2 months in addition to the above.Results： None of the patients had serious medication-related adverse reactions.After treatment,the control group showed significantly decreased NIH-CPSI scores and slightly increased IIEF-5 scores as compared with the baseline（16.5±5.9 vs 25.1±5.5,P0.05 and 13.1±5.2 vs 11.3±4.5,P0.05）,while the treatment group exhibited significant improvement in both NIH-CPSI（13.4±5.7 vs 25.5±5.3,P0.05） and IIEF-5 scores（17.5±6.5 vs 10.8±3.8,P0.05）.The total effectiveness rate for ED was significantly higher in the treatment than in the control group（74.2% vs 20%,P0.05）.Conclusion： Compound Xuanju Capsule can significantly alleviate both the symptoms of chronic prostatitis and ED in the treatment of chronic prostatitis patients with ED.
出处
《中华男科学杂志》
CAS
CSCD
2012年第10期950-952,共3页
National Journal of Andrology
